The association of angiostatin and plasminogen plasma levels with Charlson comorbidity burden and mortality in COVID-19.

IF 2.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Journal of Thrombosis and Thrombolysis Pub Date : 2026-08-01 Epub Date: 2026-05-18 DOI:10.1007/s11239-026-03289-1
Aleksandra Franczak, Paul Calistrate-Petre, Irina Dinu, Paul Jurasz
{"title":"The association of angiostatin and plasminogen plasma levels with Charlson comorbidity burden and mortality in COVID-19.","authors":"Aleksandra Franczak, Paul Calistrate-Petre, Irina Dinu, Paul Jurasz","doi":"10.1007/s11239-026-03289-1","DOIUrl":null,"url":null,"abstract":"<p><p>Severe COVID-19 is associated with thrombotic complications. Dysregulated fibrinolysis, marked by increased plasminogen activator inhibitor-1 (PAI-1) and reduced plasmin generation, has been linked to adverse outcomes including death. Plasmin(ogen) is also the precursor of angiostatin, an angiogenesis inhibitor with dual roles both preventing SARS-CoV-2 infection and promoting cell death. While alterations in fibrinolytic markers are associated with disease severity, the relationship between plasminogen and angiostatin with survival outcomes remains unclear. Therefore we compared plasma angiostatin and plasminogen levels between COVID-19 survivors and non-survivors and assessed their association with mortality. The observational cohort study included age- and sex-matched hospitalized COVID-19 survivors and non-survivors. Plasma samples were collected during hospitalization, and angiostatin and plasminogen levels were quantified by immunoblotting. Cox regression, adjusted for Charlson comorbidity score and time from symptom onset to sample collection, assessed their association with mortality. Non-survivors had a higher Charlson score and significantly lower plasma angiostatin and plasminogen levels compared to survivors. Angiostatin was not associated with mortality after multivariate analysis. However, exploratory Kaplan-Meier survival curve analysis suggested that individuals with lowest Charlson score and angiostatin within the lower tertile exhibit lowest survival probability, while individuals with high Charlson score and with angiostatin in the middle tertile exhibit longest survival probability. By contrast, lower plasminogen was independently associated with mortality after adjustments, supporting a role for impaired fibrinolysis in poor outcomes, while a more complex potential association between angiostatin and COVID-19 mortality is emerging consistent with its dual roles in SARS-CoV-2 infection.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1591-1599"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Thrombolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11239-026-03289-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Severe COVID-19 is associated with thrombotic complications. Dysregulated fibrinolysis, marked by increased plasminogen activator inhibitor-1 (PAI-1) and reduced plasmin generation, has been linked to adverse outcomes including death. Plasmin(ogen) is also the precursor of angiostatin, an angiogenesis inhibitor with dual roles both preventing SARS-CoV-2 infection and promoting cell death. While alterations in fibrinolytic markers are associated with disease severity, the relationship between plasminogen and angiostatin with survival outcomes remains unclear. Therefore we compared plasma angiostatin and plasminogen levels between COVID-19 survivors and non-survivors and assessed their association with mortality. The observational cohort study included age- and sex-matched hospitalized COVID-19 survivors and non-survivors. Plasma samples were collected during hospitalization, and angiostatin and plasminogen levels were quantified by immunoblotting. Cox regression, adjusted for Charlson comorbidity score and time from symptom onset to sample collection, assessed their association with mortality. Non-survivors had a higher Charlson score and significantly lower plasma angiostatin and plasminogen levels compared to survivors. Angiostatin was not associated with mortality after multivariate analysis. However, exploratory Kaplan-Meier survival curve analysis suggested that individuals with lowest Charlson score and angiostatin within the lower tertile exhibit lowest survival probability, while individuals with high Charlson score and with angiostatin in the middle tertile exhibit longest survival probability. By contrast, lower plasminogen was independently associated with mortality after adjustments, supporting a role for impaired fibrinolysis in poor outcomes, while a more complex potential association between angiostatin and COVID-19 mortality is emerging consistent with its dual roles in SARS-CoV-2 infection.

血管抑制素和纤溶酶原血浆水平与COVID-19患者Charlson合并症负担和死亡率的关系
严重的COVID-19与血栓性并发症有关。纤维蛋白溶解失调,以纤溶酶原激活物抑制剂-1 (PAI-1)增加和纤溶酶生成减少为标志,与包括死亡在内的不良结局有关。纤溶蛋白(原)也是血管抑制素的前体,血管抑制素是一种血管生成抑制剂,具有预防SARS-CoV-2感染和促进细胞死亡的双重作用。虽然纤溶酶标记物的改变与疾病严重程度相关,但纤溶酶原和血管抑制素与生存结果之间的关系尚不清楚。因此,我们比较了COVID-19幸存者和非幸存者血浆血管抑制素和纤溶酶原水平,并评估了它们与死亡率的关系。观察性队列研究包括年龄和性别匹配的住院COVID-19幸存者和非幸存者。住院期间采集血浆样本,免疫印迹法测定血管抑制素和纤溶酶原水平。Cox回归,调整了Charlson合并症评分和从症状出现到样本收集的时间,评估了它们与死亡率的关系。与幸存者相比,非幸存者的Charlson评分较高,血浆血管抑制素和纤溶酶原水平明显较低。多变量分析表明,血管抑制素与死亡率无关。然而,探索性Kaplan-Meier生存曲线分析表明,低分位数的Charlson评分和血管抑制素最低的个体生存概率最低,而高分位数的Charlson评分和血管抑制素在中间分位数的个体生存概率最长。相比之下,较低的纤溶酶原与调整后的死亡率独立相关,支持纤维蛋白溶解受损在不良结局中的作用,而血管抑制素与COVID-19死亡率之间更复杂的潜在关联正在出现,与其在SARS-CoV-2感染中的双重作用一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.20
自引率
0.00%
发文量
112
审稿时长
4-8 weeks
期刊介绍: The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research and patient care. The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular science. Published works will also define platforms for translational research, drug development, clinical trials and patient-directed applications. The Journal of Thrombosis and Thrombolysis'' integrated format will expand the reader''s knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书